MicroRNAs in gastrointestinal cancer: Prognostic significance and potential role in chemoresistance

Expert Opinion on Biological Therapy

Volumn 14, Issue 8, 2014, Pages 1103-1111

  Hong, Liu ^a   Han, Yu ^a   Yang, Jianjun ^a   Zhang, Hongwei ^a   Zhao, Qingchuan ^a   Wu, Kaichun ^a   Fan, Daiming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Colon cancer; Drug resistance; Esophageal cancer; Gastric cancer; MicroRNA; Rectal cancer

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; FLUOROURACIL; MICRORNA; ANTINEOPLASTIC AGENT; TUMOR MARKER;

CANCER PROGNOSIS; CANCER RESISTANCE; COLON CANCER; DIGESTIVE SYSTEM CANCER; ESOPHAGUS CANCER; HUMAN; RECTUM CANCER; REVIEW; STOMACH CANCER; DRUG RESISTANCE; GASTROINTESTINAL NEOPLASMS; GENETICS; ONCOGENE; PHYSIOLOGY; PROGNOSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GASTROINTESTINAL NEOPLASMS; HUMANS; MICRORNAS; ONCOGENES; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84903984155     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2014.907787     Document Type: Review

References (71)

1. Clayton P. Novel therapeutic strategies in infection and cancer management. Curr Aging Sci 2012;5:218-24
2. Burris HA III. Overcoming acquired resistance to anticancer therapy: Focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol 2013;71:829-42
3. Rebucci M, Michiels C. Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol 2013;85:1219-26
4. Hong L, Han Y, Lu Q, et al. Drug resistance-related microRNAs in esophageal cancer. Expert Opin Biol Ther 2012;12:1487-94
5. Butler EB, Zhao Y, Mun?oz-Pinedo C, et al. Stalling the engine of resistance: Targeting cancer metabolism to overcome therapeutic resistance. Cancer Res 2013;73:2709-17
6. Salehan MR, Morse HR. DNA damage repair and tolerance: A role in chemotherapeutic drug resistance. Br J Biomed Sci 2013;70:31-40
7. Di Leva G, Croce CM. miRNA profiling of cancer. Curr Opin Genet Dev 2013;23:3-11
8. Aguda BD. Modeling microRNAtranscription factor networks in cancer. Adv Exp Med Biol 2013;774:149-67
9. Yates LA, Norbury CJ, Gilbert RJ. The long and short of microRNA. Cell 2013;153:516-19
10. Hong L, Han Y, Li S, et al. The malignant phenotype-Associated microRNA in gastroenteric, hepatobiliary and pancreatic carcinomas. Expert Opin Biol Ther 2010;10:1693-701
11. Pencheva N, Tavazoie SF. Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol 2013;15:546-54
12. Schepeler T. Emerging roles of microRNAs in the Wnt signaling network. Crit Rev Oncog 2013;18:357-71
13. Chou J, Shahi P, Werb Z. microRNA-mediated regulation of the tumor microenvironment. Cell Cycle 2013;12:3262-71
14. Hong L, Han Y, Zhou Y, Nita A. Angiogenesis-related microRNAs in colon cancer. Expert Opin Biol Ther 2013;13:77-84
15. Hong L, Yang Z, Ma J, Fan D. Function of miRNA in controlling drug resistance of human cancers. Curr Drug Targets 2013;14:1118-27
16. Baer C, Claus R, Plass C. Genome-wide epigenetic regulation of miRNAs in cancer. Cancer Res 2013;73:473-7
17. Hong L, Li S, Han Y, et al. Angiogenesis-related molecular targets in esophageal cancer. Expert Opin Investig Drugs 2011;20:637-44
18. Spechler SJ. Barrett esophagus and risk of esophageal cancer: A clinical review. JAMA 2013;310:627-36
19. Ko MA, Zehong G, Virtanen C, et al. MicroRNA expression profiling of esophageal cancer before and after induction chemoradiotherapy. Ann Thorac Surg 2012;94:1094-102
20. Imanaka Y, Tsuchiya S, Sato F, et al. MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma. J Hum Genet 2011;56:270-6
21. Wu Y, Xiao Y, Ding X, et al. A miR-200b/200c/429-binding site polymorphism in the 3' untranslated region of the AP-2alpha gene is associated with cisplatin resistance. PLoS One 2011;6:e29043
22. Hamano R, Miyata H, Yamasaki M, et al. Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin Cancer Res 2011;17:3029-38
23. Tanaka K, Miyata H, Yamasaki M, et al. Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer. Ann Surg Oncol 2013;20:S607-15
24. Zhang H, Li M, Han Y, et al. Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci 2010;55:2545-51
25. Hummel R, Watson DI, Smith C, et al. Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg 2011;15:429-38
26. Sugimura K, Miyata H, Tanaka K, et al. Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma. Clin Cancer Res 2012;18:5144-53
27. Hong L, Han Y, Zhang H, et al. The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg 2010;251:1056-63
28. Zhou Y, Hong L. Prediction value of miR-483 and miR-214 in prognosis and multidrug resistance of esophageal squamous cell carcinoma. Genet Test Mol Biomarkers 2013;17:470-4
29. Gigek CO, Chen ES, Calcagno DQ, et al. Epigenetic mechanisms in gastric cancer. Epigenomics 2012;4:279-94
30. Wang Y, Gu X, Li Z, et al. microRNA expression profiling in multidrug resistance of the 5-Fu-induced SGC-7901 human gastric cancer cell line. Mol Med Rep 2013;7:1506-10
31. Fang Y, Shen H, Li H, et al. miR-106a confers cisplatin resistance by regulating PTEN/Akt pathway in gastric cancer cells. Acta Biochim Biophys Sin 2013;45:963-72
32. Zhang Y, Lu Q, Cai X. MicroRNA-106a induces multidrug resistance in gastric cancer by targeting RUNX3. FEBS Lett 2013;587:3069-75
33. Zhu W, Shan X, Wang T, et al. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010;127:2520-9
34. Chen Y, Zuo J, Liu Y, et al. Inhibitory effects of miRNA-200c on chemotherapy-resistance and cell proliferation of gastric cancer SGC7901/ DDP cells. Chin J Cancer 2010;29:1006-11
35. Hong L, Han Y, Zhang Y, et al. MicroRNA-21: A therapeutic target for reversing drug resistance in cancer. Expert Opin Ther Targets 2013;17:1073-80
36. Yang SM, Huang C, Li XF, et al. miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. Toxicology 2013;306:162-8
37. Liu D, Sun Q, Liang S, et al. MicroRNA-27a inhibitors alone or in combination with perifosine suppress the growth of gastric cancer cells. Mol Med Rep 2013;7:642-8
38. Zhao X, Yang L, Hu J. Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J Exp Clin Cancer Res 2011;30:55
39. Kim CH, Kim HK, Rettig RL, et al. miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genomics 2011;4:79
40. Liu K, Qian T, Tang L, et al. Decreased expression of microRNA let-7i and its association with chemotherapeutic response in human gastric cancer. World J Surg Oncol 2012;10:225
41. Riedy M. Preventing colorectal cancer. Adv NPs PAs 2013;4:18-21
42. Akao Y, Noguchi S, Iio A, et al. Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett 2011;300:197-204
43. Song B, Wang Y, Xi Y, et al. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 2009;28:4065-74
44. Chai H, Liu M, Tian R, et al. miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines. Acta Biochim Biophys Sin 2011;43:217-25
45. Boni V, Bitarte N, Cristobal I, et al. miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-Transcriptional thymidilate synthase regulation. Mol Cancer Ther 2010;9:2265-75
46. Valeri N, Gasparini P, Braconi C, et al. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci USA 2010;107:21098-103
47. Yu Y, Kanwar SS, Patel BB, et al. MicroRNA-21 induces stemness by downregulating transforming growth factor beta receptor 2 (TGFbetaR2) in colon cancer cells. Carcinogenesis 2012;33:68-76
48. Kitade Y, Akao Y. MicroRNAs and their therapeutic potential for human diseases: MicroRNAs, miR-143 and-145, function as anti-oncomirs and the application of chemically modified miR-143 as an anti-cancer drug. J Pharmacol Sci 2010;114:276-80
49. Pichler M, Winter E, Stotz M, et al. Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-Targeted agents in colorectal cancer. Br J Cancer 2012;106:1826-32
50. Borralho PM, Kren BT, Castro RE, et al. MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells. FEBS J 2009;276:6689-700
51. Pu J, Bai D, Yang X, et al. Adrenaline promotes cell proliferation and increases chemoresistance in colon cancer HT29 cells through induction of miR-155. Biochem Biophys Res Commun 2012;428:210-15
52. Svoboda M, Sana J, Fabian P, et al. MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Radiat Oncol 2012;7:195
53. Wu H, Huang M, Lu M, et al. Regulation of microtubule-Associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel. Cancer Chemother Pharmacol 2013;71:1159-71
54. Ji Q, Hao X, Meng Y, et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008;8:266
55. Chen J, Chen Y, Chen Z. MiR-125a/b regulates the activation of cancer stem cells in paclitaxel-resistant colon cancer. Cancer Invest 2013;31:17-23
56. Li J, Zhang Y, Zhao J, et al. Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells. Mol Cell Biochem 2011;357:31-8
57. Li J, Chen Y, Zhao J, et al. miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression. Cancer Lett 2011;304:52-9
58. Zhu W, Zhu D, Lu S, et al. miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol 2012;29:384-91
59. Xia L, Zhang D, Du R, et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008;123:372-9 (Pubitemid 351842022)
60. Wang F, Li T, Zhang B, et al. MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun 2013;434:688-94
61. Xu K, Liang X, Shen K, et al. MiR-222 modulates multidrug resistance in human colorectal carcinoma by down-regulating ADAM-17. Exp Cell Res 2012;318:2168-77
62. Qu J, Zhao L, Zhang P, et al. MicroRNA-195 chemosensitizes colon cancer cells to the chemotherapeutic drug doxorubicin by targeting the first binding site of BCL2L2 mRNA. J Cell Physiol 2013;PubMed PMID: 23526568
63. Bitarte N, Bandres E, Boni V, et al. MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells 2011;29:1661-71
64. Mencia N, Selga E, Noé V, et al. Underexpression of miR-224 in methotrexate resistant human colon cancer cells. Biochem Pharmacol 2011;82:1572-82
65. Hodzic J, Giovannetti E, Diosdado B, et al. Regulation of deoxycytidine kinase expression and sensitivity to gemcitabine by micro-RNA 330 and promoter methylation in cancer cells. Nucleosides Nucleotides Nucleic Acids 2011;30:1214-22
66. Xu K, Liang X, Cui D, et al. miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drugsensitivity in human colorectal carcinoma cells. Mol Carcinog 2013;52:70-8
67. Wu XM, Shao XQ, Meng XX, et al. Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells. Acta Pharmacol Sin 2011;32:259-69
68. Tong JL, Zhang CP, Nie F, et al. MicroRNA 506 regulates expression of PPAR alpha in hydroxycamptothecinresistant human colon cancer cells. FEBS Lett 2011;585:3560-8
69. Lynam-Lennon N, Reynolds JV, Marignol L, et al. MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma. J Mol Med 2012;90:1449-58
70. Wang F, Song X, Li X, et al. Noninvasive visualization of microRNA-16 in the chemoresistance of gastric cancer using a dual reporter gene imaging system. PLoS One 2013;8:e61792
71. Li H, Yang BB. Friend or foe: The role of microRNA in chemotherapy resistance. Acta Pharmacol Sin 2013;34:870-9.